Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11662667 | 0.81 | — | — | |
| SCHEMBL31263122 | 0.78 | — | — | |
| SCHEMBL11656475 | 0.75 | — | — | |
| SCHEMBL5986776 | 0.71 | — | — | |
| SCHEMBL31263245 | 0.71 | LMNA (0.33) | CYP3A4 | |
| SCHEMBL11558911 | 0.71 | CYP3A4 (0.32) | CYP3A4 | |
| SCHEMBL18306972 | 0.71 | CYP3A4 (0.36) | CYP3A4 | |
| SCHEMBL18988485 | 0.71 | — | — | |
| SCHEMBL2404479 | 0.69 | — | — | |
| SCHEMBL18306938 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688642-B2 | Substituted pyrazines as GPR40 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | claimed |
| EP-3033337-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | Janssen Pharmaceutica, N.V. (BE) | 2016-06-22 | — | — | EP | claimed |
| US-20160009662-A1 | PYRAZINE GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-14 | — | — | US | claimed |
| WO-2016007714-A1 | PYRAZINE GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-14 | — | — | WO | claimed |
| WO-2015023289-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-19 | — | — | WO | claimed |
| JP-55020708-A | — | — | None | — | — | JP | disclosed |
| JP-53112878-A | — | — | None | — | — | JP | disclosed |
| JP-53116375-A | — | — | None | — | — | JP | disclosed |
| EP-4739685-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-12595253-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-12421213-B2 | Benzamides of pyrazolylamino- pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2025-09-23 | — | — | US | disclosed |
| US-8134001-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2229396-B1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | disclosed |
| EP-2229396-A1 | SPIROINDOLINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009077357-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-20090156610-A1 | Spiroindolinone Derivatives | DING QINGJIE | 2009-06-18 | — | — | US | disclosed |
| JP-S5520708-A | PREPARATION OF NITROGEN-CONTAINING COMPOUND | MITSUI PETROCHEM IND LTD | 1980-02-14 | — | — | JP | disclosed |
| JP-S53116375-A | PURIFICATION OF 2,2,6,6-TETRAMETHYLHYDROPIRAN-4-OL | MITSUI PETROCHEM IND LTD | 1978-10-11 | — | — | JP | disclosed |
| JP-S53112878-A | PRODUCTION OF 2,2,6,6,-TETRAMETHYLTETRAHYDROPYRAN-4-OL | MITSUI PETROCHEM IND LTD | 1978-10-02 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156610-A1 | Spiroindolinone Derivatives | SDHA, AR, XPOT | CYP3A4 185/4885 |
| US-12595253-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | JAK1, JAK3, JAK2 | CYP3A4 1365/4885 |
| US-12421213-B2 | Benzamides of pyrazolylamino- pyrimidinyl derivatives, and compositions and methods thereof | JAK2, JAK1, JAK3 | CYP3A4 597/4885 |
| US-20160009662-A1 | PYRAZINE GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR52 | CYP3A4 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.